Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Product Type
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

SW106065 is an anticancer agent.1 It decreases the proliferation of S462 and SNF96.2 neurofibroma cells (EC50s = 439 and 753.6 nM). SW106065 (2.5 µM) induces apoptosis and cell cycle arrest at the G1/G0 and G2/M phases in primary patient-derived malignant peripheral nerve sheath tumor (MPNST) cells. In vivo, SW106065 (40 mg/kg twice per day) decreases tumor volume in a patient-derived xenograft (PDX) mouse model of MPNSTs. It also reduces influenza A H1N1 and H3N2 strain replication in MDCK cells (EC50s = 0.17 and 0.085 µM, respectively) with a 50% cytotoxicity concentration (CC50) value of 36 µM.2
WARNING This product is not for human or veterinary use.
1. Preclinical therapeutic efficacy of a novel pharmacologic inducer of apoptosis in malignant peripheral nerve sheath tumors. Cancer Res. 74(2), 586-597 (2014).
2. A broad influenza virus inhibitor acting via IMP dehydrogenase and in synergism with ribavirin. Antiviral Res. 196, 105208 (2021).